MENU
News
CME
Journals
All Specialties
All Specialties
Aesthetics
Allergy/Immunology
Cardiac/Vascular Intervention
Cardiology
Dermatology
Endocrinology
Gastroenterology
Hematology/Oncology
Hepatology
Infectious Disease
Nephrology
Neurology
Ophthalmology
Optometry
Orthopedics
Pediatrics
Primary Care
Psychiatry
Pulmonology
Rheumatology
Infectious Disease
All Subspecialties
All Subspecialties
Antimicrobials
Dermatology
Emerging Diseases
Gastrointestinal Infections
Hepatitis C
HIV/AIDS
Influenza
MRSA
Nosocomial Infections
Pediatric ID
Practice Management
Respiratory Infections
STDs
Vaccination
Zoonotic Infections
More
Resources
Meeting News
Opinion
Meeting Calendar
Current Issues
Healio Jobs
Account
Log Out
Log In
News
Search
News
CME
Journals
Log In
Log Out
All Specialties
All Specialties
Aesthetics
Allergy/Immunology
Cardiac/Vascular Intervention
Cardiology
Dermatology
Endocrinology
Gastroenterology
Hematology/Oncology
Hepatology
Infectious Disease
Nephrology
Neurology
Ophthalmology
Optometry
Orthopedics
Pediatrics
Primary Care
Psychiatry
Pulmonology
Rheumatology
All Subspecialties
All Subspecialties
Antimicrobials
Dermatology
Emerging Diseases
Gastrointestinal Infections
Hepatitis C
HIV/AIDS
Influenza
MRSA
Nosocomial Infections
Pediatric ID
Practice Management
Respiratory Infections
STDs
Vaccination
Zoonotic Infections
Resources
Meeting News
Opinion
Meeting Calendar
Current Issues
Healio Jobs
Search
Healio
News
Infectious Disease
Current Issues
HCV Next Current Issue
Related Resources
About Us
Advertising Information
Contact the Editor
Editorial Policy and Philosophy
Meet the Editorial Board
Mission Statement
Order Article Reprints
Subscribe
Renew
Year
2018
2017
2016
2015
2014
Issue
January/February
March/April
May/June
July/August
September/October
November/December
View Issue
The following articles appeared in the print edition of
HCV Next
.
Table of Contents
HCV Next in Retrospect: Looking Back at ‘Your Guide to the Age After Interferon’
Gilead announces launch of Epclusa, Harvoni generics for HCV
HCV: The End of the Evolution, the Beginning of the Social Science
Ira M. Jacobson, MD
Passing the Torch from Implementation to Eradication
Michael S. Saag, MD
What’s Next for HCV Next: From Approval to Nearly 100% Cure Rates, Saying Goodbye
Katrina Altersitz
HCV eradication program achieves 97% cure among patients on dialysis
Louisiana Developing ‘Netflix’ Style Subscription Plan for HCV Treatment
EXPEDITION-8: Mavyret nearly perfect in 8-week regimen
HBV rates rising in women from same U.S. regions with drug-related HCV
HCV reinfection uncommon in injection drug users after treatment
Universal screening for HCV superior to risk-based approach in pregnant women
Related Resources
About Us
Advertising Information
Contact the Editor
Editorial Policy and Philosophy
Meet the Editorial Board
Mission Statement
Order Article Reprints
Subscribe
Renew
